Navana Pharmaceuticals Limited's profit rose 28.25 per cent year-on-year to Tk 11.71 crore in the January-March quarter of the current financial year.

The pharmaceuticals manufacturer made a profit of Tk 9.13 crore in the third quarter of 2021-22.

Thus, the earnings per share were Tk 1.09 in January-March of FY23 against Tk 0.85 in the identical quarter of FY22, according to the unaudited financial statements.

The EPS increased due to a rise in gross profit and a decrease in corporate tax, said Navana Pharmaceuticals in a filing on the Dhaka Stock Exchange today.

The profit rose to Tk 27.61 crore in the July-March of the current financial year, a rise of 7.55 per cent from Tk 25.67 crore recorded in the same nine-month period of FY22.

The EPS was Tk 2.57 in July-March of FY23. It was Tk 2.39 in the same period of FY22.